ProCE Banner Activity

Thoughts on Recent Advances With Precision Medicine in Cervical Cancer

Clinical Thought

Read this commentary from Ritu Salani, MD, MBA, and Rachel Frankenthal, PA-C, MPH, to learn about recent advances in precision medicine for cervical cancer.

Released: May 31, 2022

Expiration: May 30, 2023

No longer available for credit.

Share

Faculty

Rachel Frankenthal

Rachel Frankenthal, PA-C, MPH

Physician Assistant
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Acknowledgement

This activity is supported by educational grants from AstraZeneca; GlaxoSmithKline; and Merck Sharp & Dohme Corp.

Supporters

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Target Audience

NPs and PAs in oncology

Disclosure

Rachel Frankenthal, PA-C, MPH has no relevant financial relationships to disclose.

Ritu Salani, MD, MBA: consultant/advisor/speaker: Arcus Biosciences, Genentech, GlaxoSmithKline, Instil Bio, Merck, Regeneron, Seagen.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Format

Clinical Thought

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.